Key facts
- Notable investors include SciFounders.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Moab Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Moab Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Moab Therapeutics
Developer of modular therapeutic agents designed for targeted biological intervention. The company utilizes bio-inspired scaffolds with antibody-like potency, incorporates machine learning-guided molecular design, and emphasizes high stability and translatability across applications, enabling biomedical researchers and pharmaceutical developers enhanced precision, adaptability, and efficiency in addressing complex disease mechanisms and advancing next-generation treatment modalities.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2025
- Employees
- 3
- Website
- moabtx.bio/
- Ownership
- Privately Held (backing)
Moab Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Moab Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Moab Therapeutics in its N-PORT filings yet. We sweep new filings monthly.